Cure8 research brief
Patients and clinicians use the term "disease burden" to describe more than inflammation alone; it affects symptoms, daily function, mental health, and healthcare use. A clearer, integrated way to measure burden could improve care decisions and research that reflects what matters to people with Crohn's.
Clinicians treating Crohn's disease, researchers developing outcome measures or trials, and adult patients interested in patient-reported outcomes and holistic care.
The review highlights that "disease burden" is used in many ways across research and clinical literature. Current measures tend to be siloed (for example, clinical tests separate from quality-of-life or economic measures), which can miss the full, multidimensional impact of Crohn's disease on people and health systems.
This gap means researchers and clinicians lack a validated, integrated tool to track biological disease activity alongside symptoms, function, and costs over time. Developing longitudinal, multidimensional measurement tools could help guide more holistic care and better capture outcomes that matter to patients.
Practical takeaway: If you follow research or clinical care for Crohn's disease, expect future efforts to push for combined clinical and patient-centered outcome measures—until then, discussions about "disease burden" may vary depending on which outcomes a study or clinician emphasizes.
This article is a systematic literature review (PROSPERO-registered) summarized from the journal abstract; it synthesises existing studies but does not present new patient-level trial data. The review notes heterogeneity and lack of integrated longitudinal tools—findings framed as a gap and a recommendation for future tool development.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Digital health tools could offer more continuous monitoring and self-management support for people with IBD, potentially helping detect flares earlier and improve quality of life. This review collects existing evidence...
Sarcopenia or low muscle mass may be linked with worse endoscopic healing and reduced durability of biologic therapy in IBD, particularly Crohn's disease, which could matter for prognosis and treatment planning if...
The study suggests people with Crohn's disease or ulcerative colitis have higher lipoprotein(a) levels than healthy controls, which could be relevant because Lp(a) is a cardiovascular-risk biomarker and cardiovascular...
